Neuronetics, Inc. (STIM) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Neuronetics, Inc.'s filing signal turned negative.

Neuronetics, Inc. is a neuroscience company focused on delivering in-office treatments for mental health disorders, primarily using its NeuroStar Advanced Therapy System. This non-invasive transcranial magnetic stimulation (TMS) device is FDA-cleared for treating major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and MDD with comorbid anxiety symptoms in adults and adolescents. The company also operates Greenbrook treatment centers, offering TMS and SPRAVATO(R) (esketamine nasal spray) for depression. Neuronetics believes it leads the TMS market, having treated an estimated 237,574 patients globally with over 8.5 million sessions by the end of 2025, generating $149.2 million in revenue that year. Its strategy includes expanding commercialization in the U.S. and internationally, particularly in Japan.

Revenue is primarily driven by clinic revenue (59% of U.S. revenue in 2025) and treatment session revenue (30% of U.S. revenue in 2025), with capital sales of the NeuroStar Advanced Therapy System accounting for the remainder. International revenues represented 2% of total revenues in 2025.